

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported)**

January 22, 2020

---

**Vir Biotechnology, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39083**  
(Commission  
File Number)

**81-2730369**  
(IRS Employer  
Identification No.)

**499 Illinois Street, Suite 500**  
**San Francisco, California 94158**  
(Address of principal executive offices, including zip code)

**(415) 906-4324**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	VIR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01 Other Events.**

On January 22, 2020, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing that it is applying two of its platforms to potentially address the public health risk from Wuhan coronavirus. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.****(d) Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release of the Company, dated January 22, 2020.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 23, 2020

**VIR BIOTECHNOLOGY, INC.**

By: /s/ Howard Horn  
Howard Horn  
Chief Financial Officer



**Vir Biotechnology applying multiple platforms to  
address public health risk from Wuhan coronavirus**

**SAN FRANCISCO – January 22, 2020** - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing the following in response to inquiries from multiple academic, government, investor, and media stakeholders.

Vir is working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV, also referred to as “Wuhan coronavirus”.

“We have a library of multiple fully-human mAbs that bind and neutralize coronaviruses such as SARS and MERS,” said Herbert “Skip” Virgin, M.D., Ph.D., Chief Scientific Officer of Vir. “These mAbs were discovered using our antibody platform that identifies mAbs from survivors of an infection. Some of these mAbs are able to neutralize zoonotic coronaviruses, and we believe may have the potential to treat and prevent Wuhan coronavirus. We are also exploring the isolation of new mAbs specific for this virus.”

In addition to Vir’s mAb efforts, its scientists are planning to apply whole genome CRISPR-based screening capabilities (Vir’s innate immunity platform) to identify the host receptor that allows Wuhan coronavirus infection. This may allow additional approaches to address this rapidly emerging public health concern.

“We appreciate the threat this pathogen presents, and are utilizing our technologies to determine whether we currently have, or can identify, therapies to neutralize this virus,” said George Scangos, Ph.D., Chief Executive Officer of Vir. “We don’t know yet if these efforts will be successful, but we are working aggressively to find out.”

**About Vir Biotechnology**

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit [www.vir.bio](http://www.vir.bio).

---

## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding plans to apply Vir’s innate immunity platform to identify the host receptor that allows Wuhan coronavirus infection and the likelihood Vir’s antibodies and approaches can address the virus. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

### **Contact:**

**Vir Biotechnology, Inc.**

### **Investors**

Neera Ravindran, MD  
Head of Investor Relations & Strategic Communications  
[nravindran@vir.bio](mailto:nravindran@vir.bio)  
+1-415-506-5256

### **Media**

Lindy Devereux  
Scient PR  
[lindy@scientpr.com](mailto:lindy@scientpr.com)  
+1-646-515-5730